Cincinnati Children's partners with drug firm to manage medical innovations – The Cincinnati Enquirer
Cincinnati Children’s Hospital Medical Center has partnered with an innovation district-based drug firm to develop and commercialize novel therapeutics discovered by its own researchers.
The collaboration, announced Wednesday, teams the hospital with Orange Grove Bio, a preclinical drug investment and development firm that moved its headquarters from New York to the Cincinnati Innovation District last year after it labeled the area as an “up-and-coming hub” of biopharmaceutical research.
Orange Grove Bio:Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Under the collaboration, Orange Grove Bio, which also has a partnership with the University of Cincinnati, will support and advise emerging technologies that sprout from Cincinnati Children’s Innovation Ventures team. According to a news release, the partnership “aims to increase entrepreneurship and education as well as boost promising technologies emerging from Cincinnati Children’s,” and will focus in the areas of autoimmune and inflammatory diseases, oncology and cell and gene therapies.
Cincinnati Children’s has developed a number of medical innovations over the years, including the development of the Sabin oral polio vaccine, a vaccine to combat rotavirus, and the identification of surfactant proteins as a routine treatment for respiratory distress syndrome, among others.
Orange Grove Bio is located in the renovated 1819 Innovation Hub, which is the former Sears building located on Reading Road.